Department of Health and Aging Australia. The Review of the AR-DRG Classification System Development Process: Brisbane, QLD, Australia: PricewaterhouseCoopers; 2009. 2. Klein-Hitpass U, ...

A previous study demonstrated that power against the (unobserved) true effect for the primary end point (PEP) of most phase III oncology trials is low, suggesting an increased risk of false-negative ...